Market Dashboard LogoDaily Marketwith AI friends
  1. Home/
  2. quote/
  3. biib
Logos provided by Logo.dev© DailyMarket.io MarketWithFriends.com 2025 All rights reserved.This is not financial advice. Please do your own research or consult a licensed financial advisor.Market information and analysis may be delayed by several minutes to several hours and is provided for informational purposes only.
BIIB logo

Biogen Inc.

BIIB

Exchange:NMSType:EquityIndustry:Drug Manufacturers - GeneralSector:HealthcareEmployees:7,605Website:www.biogen.comCurrency:USD
Market Cap$18.84B
Volume366.83K
Revenue$9.82B
Gross Profits$7.43B
Trailing P/E12.71

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRID...

Price Chart

Track all markets on TradingView

AI Summary

ModelNear-Term (0-3 mo.)Mid-Term (3-12 mo.)Long-Term (1-5 yr.)
DeepseekBuyHoldBuy
OpenAIBuyHoldBuy
GeminiBuyHoldHold
GrokBuyHoldBuy

Detailed Analysis

Deepseek
Buynear term

Current price above 50-day average suggests short-term momentum.

Valuation:Low forward PE indicates undervaluation.
Technical:Price above 50-day average, below 200-day average.
Sentiment:Low beta suggests less volatility.
News:Monitor for sector-specific news.
Holdmid term

Potential for recovery but watch for sector trends.

Valuation:Undervalued but depends on earnings growth.
Technical:Needs to break 200-day average for bullish signal.
Sentiment:Stable but dependent on healthcare sector performance.
News:Pipeline developments could impact valuation.
Buylong term

Strong sector fundamentals and undervaluation offer long-term growth.

Valuation:Attractive for long-term investors seeking value.
Technical:Long-term averages may provide support.
Sentiment:Healthcare sector expected to grow steadily.
News:Innovation in biotech could drive future performance.
Gemini
Buynear term

The stock is trading above its 50-day average, indicating positive momentum, and is undervalued based on its forward P/E.

Valuation:Low forward P/E suggests undervaluation.
Technical:Price above 50-day average indicates upward trend.
Sentiment:Likely positive due to recent price increase.
News:Needs assessment based on recent news.
Holdmid term

While undervalued, the stock is below its 200-day average, and long-term growth depends on pipeline developments.

Valuation:Attractive forward P/E ratio.
Technical:Price below 200-day average suggests caution.
Sentiment:Neutral, pending further catalysts.
News:Pipeline progress is crucial.
Holdlong term

Long-term performance hinges on successful drug development and market adoption, creating uncertainty.

Valuation:Current valuation is attractive, but future growth is key.
Technical:Long-term trend needs confirmation.
Sentiment:Dependent on clinical trial outcomes.
News:Drug approvals are critical.
Openai
Buynear term

BIIB shows a promising rebound from recent lows, suggesting a short-term buying opportunity.

Valuation:Attractive forward PE ratio indicates undervaluation.
Technical:Price above 50-day average but below 200-day signals potential recovery.
Sentiment:Market sentiment may improve with positive technical signals.
News:No major news impacting short-term valuation.
Holdmid term

Pending further developments, maintaining position is advisable as market adjusts.

Valuation:Valuation remains attractive, but market needs time to recognize.
Technical:Needs to stabilize above 200-day average for stronger confidence.
Sentiment:Dependent on broader market trends and sector performance.
News:Watch for any strategic shifts or regulatory changes.
Buylong term

Long-term growth potential in healthcare sector makes BIIB a solid investment.

Valuation:Consistently low PE ratio suggests long-term undervaluation.
Technical:Long-term indicators should improve with sector growth.
Sentiment:Healthcare sector stability and growth enhances long-term sentiment.
News:Innovation and expansion in biotech could drive future gains.
Grok
Buynear term

Current price above 50-day average signals short-term strength. Momentum may continue with positive technicals.

Valuation:Forward P/E of 8.12 suggests undervaluation.
Technical:Price above 50-day average indicates bullish momentum.
Sentiment:Neutral sentiment with limited recent data.
News:No major news impacting near-term outlook.
Holdmid term

Price below 200-day average suggests caution. Potential recovery may take time.

Valuation:Low forward P/E supports reasonable valuation.
Technical:Below 200-day average indicates bearish trend.
Sentiment:Mixed sentiment in healthcare sector.
News:Awaiting pipeline updates or regulatory news.
Buylong term

Low beta and valuation suggest stability. Healthcare sector offers growth potential.

Valuation:Attractive forward P/E for long-term value.
Technical:Long-term trends depend on broader market.
Sentiment:Positive long-term outlook for healthcare innovation.
News:Potential for positive developments in pipeline.

Similar Stocks

ABBV logoABBV
AbbVie Inc.
Sec: HealthcareInd: Drug Manufacturers - General
MCap: 337B
MRK logoMRK
Merck & Company, Inc.
Sec: HealthcareInd: Drug Manufacturers - General
MCap: 206B
GILD logoGILD
Gilead Sciences, Inc.
Sec: HealthcareInd: Drug Manufacturers - General
MCap: 136B
PFE logoPFE
Pfizer, Inc.
Sec: HealthcareInd: Drug Manufacturers - General
MCap: 141B